Non-small cell lung cancer (NSCLC) is heterogeneous in the genetic and environmental parameters that influence cell metabolism in culture. Here, we assessed the impact of these factors on human NSCLC metabolism in vivo using intraoperative 13 C-glucose infusions in nine NSCLC patients to compare metabolism between tumors and benign lung. While enhanced glycolysis and glucose oxidation were common among these tumors, we observed evidence for oxidation of multiple nutrients in each of them, including lactate as a potential carbon source. Moreover, metabolically heterogeneous regions were identified within and between tumors, and surprisingly, our data suggested potential contributions of non-glucose nutrients in well-perfused tumor areas. Our findings not only demonstrate the heterogeneity in tumor metabolism in vivo but also highlight the strong influence of the microenvironment on this feature.
INTRODUCTION
Tumors display altered metabolism relative to benign tissues (Hanahan and Weinberg, 2011) . These changes support abnormal survival and growth of malignant cells by providing energy, macromolecular precursors, and reducing equivalents (DeBerardinis et al., 2008) . Beyond the importance of metabolic reprogramming to cancer biology, it also has implications for clinical oncology. Targeting key metabolic activities is an effective therapeutic approach (Vander Heiden, 2011) , and the ability to image informative aspects of metabolism has made it possible to identify and characterize malignant tissue non-invasively. The most widely used form of metabolic imaging is 18 fluoro-2-deoxyglucose positron emission tomography (FDG-PET), which capitalizes on enhanced glucose uptake in tumors (Fletcher et al., 2008) .
Metabolic gene expression and metabolomics have been used to identify subclasses among individual human tumors from the same organ (Caro et al., 2012; Terunuma et al., 2014) , but it is unknown whether these differences reflect true changes in metabolic activity in vivo. Tumor metabolism is regulated by a poorly defined combination of cell-intrinsic and cell-extrinsic factors. Oncogene expression is sufficient to reprogram some aspects of nutrient utilization, suggesting that cell-autonomous metabolism is driven in part by the oncogenotype Ji et al., 2007; Son et al., 2013) . Altered perfusion from abnormal tumor vasculature is believed to be a major extrinsic driver of metabolism through effects on oxygen and substrate delivery (Guillaumond et al., 2013) . Other extrinsic effects include metabolic competition or cooperativity among stromal, immune, and tumor cells (Pavlides et al., 2009; Sonveaux et al., 2008) . A full accounting of tumor metabolism will need to consider extrinsic influences in addition to the complexity imposed by the oncogenotype.
The tumor microenvironment is difficult to model ex vivo, and this limits the use of culture-based systems to infer the metabolism of intact tumors. Stable isotopes (e.g., 13 C) are widely used to investigate cellular metabolism, because patterns of 13 C enrichment downstream of a labeled nutrient encode information about pathway activity (Buescher et al., 2015) . The safety of 13 C makes this approach feasible in humans. A few studies have provided 13 C-labeled nutrients to cancer patients during tumor resection, then analyzed 13 C enrichment in metabolites extracted from the tumor. In gliomas and brain metastases, infusions of [U- 13 C]glucose revealed metabolism of glucose through both glycolysis and the tricarboxylic acid (T) cycle (Maher et al., 2012) . In non-small cell lung cancer (NSCLC), introducing [U- glucose as a bolus revealed that both glycolysis and TCA cycle metabolism were active in the tumor (Fan et al., 2009) . Pyruvate carboxylase (PC), the enzyme converting pyruvate to oxaloacetate (OAA), was highly expressed in NSCLC and contributed to labeling differences between tumor and lung (Sellers et al., 2015) .
None of these reports assessed heterogeneity within or between tumors or the influence of cell-extrinsic factors on metabolism. Here, we incorporated clinical imaging to provide quantitative information about glucose metabolism and the tumor environment in NSCLC from nine untreated patients. We demonstrate that these tumors are heterogeneous with respect to glucose utilization and that areas of metabolic heterogeneity between and within tumors can be predicted by assessing tissue perfusion preoperatively.
RESULTS
Workflow for Preoperative Imaging, Intraoperative 13 C-Glucose Infusion, and Sample Selection Prior to surgery, tumors were assessed by FDG-PET and multiparametric MRI (mpMRI) ( Figure 1A ). mpMRI consisted of T2-weighted imaging for anatomy; diffusion-weighted imaging (DWI) to determine the apparent diffusion coefficient (ADC), a surrogate for cellularity; and dynamic contrast-enhanced MRI (DCE-MRI), which measures time-dependent entry of a contrast agent and is used to assess perfusion (Koh and Collins, 2007; Yankeelov and Gore, 2009) . Multidisciplinary conferences involving the research team, surgeon, and radiologist were held to discuss the images and plan tissue sampling. On the day of surgery, the patient had an intravenous catheter placed into each arm. One was used to deliver 8-g [U-
13 C]glucose over 10 min, followed by a continuous infusion of 8 g/hr for an average of 3 hr until the lobectomy was performed. The other was used to withdraw blood samples for analysis of 13 C enrichment in plasma glucose. This approach achieves a persistent state of high enrichment of plasma glucose (Maher et al., 2012) . After removal of the lobe, the tissue was oriented to identify anatomic landmarks and dissected to procure specific fragments prioritized by presurgical imaging. The fragments were rinsed, frozen, and subjected to histological, molecular, and metabolic analysis. Imaging and
13
C data from a 59-year-old female smoker with a grade 3 adenocarcinoma (patient 1) are in Figures 1B-1E . This tumor exceeded 22 cm 3 and was FDG-PET avid, demonstrating heterogeneous FDG signal and SUV max > 10 ( Figure 1B ; Table 1 ).
Plasma glucose enrichment exceeded 30% for 2 hr ( Figure 1C ). Histology revealed the tumor to have abundant staining for Ki67, a marker of cell proliferation, and CD31, a marker of tumor vasculature ( Figure 1D ). Metabolites were extracted from lung and from an FDG-avid, ADC-low (i.e., highly cellular) tumor fragment. For an intuitive display of how 13 C labeling compared between the tumor and lung, average relative fractional enrichments (i.e., fractional enrichment in tumor/fractional enrichment in lung) are shown for several metabolites. Glucose and the glycolytic intermediate 3-phosphoglycerate (3-PG) had somewhat lower fractional enrichments in the tumor, but all other glucose-derived metabolites, including lactate and TCA-cyclederived intermediates (citrate, glutamate, and malate), were more enriched in the tumor ( Figure 1E ; full 13 C distributions are shown in Figure S1 ). Thus, in this tumor, high FDG uptake correlated with enhanced contribution of glucose to lactate and TCA cycle intermediates.
Comparison of Bolus and Continuous Infusions of [U-
13 C]Glucose Administration Administering 13 C glucose as one or more boluses rather than a continuous infusion has been used to assess tumor metabolism in humans and mice (Fan et al., 2009; Sellers et al., 2015; Yuneva et al., 2012) . Boluses have the advantage of reduced cost and ease of administration. On the other hand, infusions may lead to improved 13 C signal, better evaluation of complex pathways requiring persistent 13 C exposure, and the possibility of achieving isotopic steady state to simplify analysis . Analysis of the TCA cycle is complicated by the fact that labeling depends not only on the route of entry but also on the number of times the cycle has turned. To compare these methods, we assessed labeling data obtained from brief versus prolonged periods of 13 C exposure. Patient 2 received an 8-g bolus of [U-
13 C]glucose, followed shortly thereafter by resection. This produced a rapid rise in glucose enrichment, but no plateau in the circulation ( Figure S2A ). Patient 3 received an 8-g bolus prior to anesthesia followed by another 8-g bolus 1 hr before surgery ( Figure S2B ). As in patient 1, enrichments in lactate (M+3) and TCA cycle intermediates (M+2 citrate, glutamate, and malate) were higher in the tumor than the lung of patients 2 and 3 ( Figure S2C ). The relative enrichment of these species was not improved by patient 1's longer infusion, but the absolute enrichments were lower in patients 2 and 3, resulting in poor signal for higher-order labeling (e.g., M+3-4 in citrate and malate; Figures  S2D and S2E ). M+1 isotopologues were also better represented after persistent 13 C glucose exposure; this form of labeling likely arises after multiple turns of the TCA cycle ( Figures S2F and 2G ). Thus, boluses are sufficient to detect abundant isotopologues but compromise assessment of other isotopologues. For these reasons, we used infusions in patients 4-9.
Enhanced Anaerobic and Aerobic Glucose Metabolism in NSCLC Table 1 and Figure S3 contain clinical and histological information from the nine patients. The tumors were heterogeneous in their tumor-lymph-nodes metastasis (TNM) stage, grade, and SUV max . Molecular analysis of EGFR and KRAS revealed EGFR mutations in four patients and KRAS mutations in two; three tumors did not contain mutations in either gene. The tumors also displayed a wide range of stromal content, microvessel density, and MIB-1 fraction (Table 1) . Plasma glucose enrichments showed the expected rapid rise in 13 C fractional enrichment due to the bolus, followed by a plateau during the infusion (Figure S4 ). Complete 13 C isotopologues from all tissue fragments are in Table S1 . Relative fractional enrichments are shown for several informative metabolites (averages in Figure 2A and data from individual fragments in Figure 2B ). All lung samples demonstrated enrichment of intermediates from glycolysis and the TCA cycle, indicating that benign lung uses both pathways (Table S1 ). These intermediates were also labeled in all tumors. Importantly, although there was substantial variability in 13 C labeling, the variability among patients far exceeded the variability among independent samples obtained from the same tumor, indicating that this technique detects biological variation in human tumor metabolism ( Figure 2C ). Despite the fact that all tumors displayed FDG uptake by PET, glucose fractional enrichment was lower on average in tumor than lung, as previously reported (Fan et al., 2009) . Lactate, by contrast, was more enriched in tumor fragments, indicating a greater propensity to convert [U-
13 C]glucose to [U-13 C]lactate than non-cancerous lung. Several metabolites related to the TCA cycle (e.g., M+2 isotopologues of acetyl-CoA, citrate, glutamate, and malate) were also more enriched in the tumors (Figures 2A and 2B) .
Although these M+2 enrichments likely reflect entry of label into the TCA cycle via the pyruvate dehydrogenase (PDH) reaction, mass spectrometry (MS) does not provide positional 13 C information. This potentially confounds the interpretation of qualitative assessment of MS isotopologues, particularly when the overall enrichment is low. M+2 isotopologues in citrate, etc., may therefore reflect PDH-dependent labeling during the first turn of the cycle, multiple turns of the cycle, or the combined effects of PC-dependent entry and multiple turns. To limit the assumptions needed to interpret the data, we analyzed several fragments by 13 C nuclear magnetic resonance (NMR) spectroscopy, which definitively assigns 13 C positions. These spectra revealed prominent 4-5 doublets in carbon 4 of glutamate, a pattern requiring PDH activity. This doublet was much more prominent in tumor than lung (Figures 3A and S5A) , and labeling of the 4-5 doublets relative to the C4 singlet was highly correlated with fractional enrichments of M+2 in citrate and glutamate ( Figure 3B ). These observations indicate that enhanced TCA cycle labeling in tumors reflects entry of uniformly labeled acetyl-coenzyme A (acetyl-CoA) into the cycle via PDH. Strong correlations between mass isotopologues lactate M+3 and citrate M+2, and between citrate M+2 and malate M+2, indicate that glycolysis, PDH, and TCA cycle activity are linked in the tumors ( Figure 3C ). To rule out artificial inflation of 13 C labeling by metabolite pool depletion (Buescher et al., 2015) , we also analyzed metabolite abundance. Glucose was less abundant in the tumors, lactate was more abundant, and TCA cycle intermediates displayed no consistent trend ( Figures S5B and S5C ). Thus, human NSCLC tumors display enhanced carbon flow through PDH and the TCA cycle compared to adjacent lung. Lung tumors contain increased expression of PC and have evidence of enhanced flux through this anaplerotic enzyme as assessed by qualitative assessment of 13 C enrichment (Sellers et al., 2015) . PC converts [U-
13
C]pyruvate into OAA M+3, which can Smoking reflects smoking history in pack-years (average packs/day 3 years smoking). Tumor size is in cm 3 measured by T2 MRI. Key for histology:
ADC, adenocarcinoma; ac, acinar; pap, papillary; LCNEC, large cell neuroendocrine carcinoma; SQCC, squamous cell carcinoma. Key for TNM staging: T1a, greatest dimension %2 cm; T1b, greatest dimension >2 cm but %3 cm; T2a, greatest dimension >3 cm but %5 cm; N0, regional node metastases absent; N1, ipsilateral peribronchial and/or ipsilateral hilar lymph nodes metastases present; MX, distant metastasis unknown; M0, distant metastases absent. Key for tumor grade: G1, well differentiated; G2, moderately differentiated; G3, poorly differentiated; G4, undifferentiated. % stroma is from a semiquantitative assessment of the fraction of area occupied by non-tumor cells. Microvessel density (MVD) is reported as number of vessels 3 10 À6 /mm 2 . Vessels were detected by CD31 IHC. MIB-1 is the fraction of cells with nuclear Ki67 staining. ND, no mutations detected; NA, tissue or images not available.
condense with unlabeled acetyl-CoA to produce citrate M+3 and equilibrate with malate to produce malate M+3. Fractional enrichments of malate, citrate and glutamate M+3 were higher in tumor than lung ( Figure 3D ), although the absolute abundance of these species was much lower than PDH-derived isotopologues (Table  S1 ). Citrate M+5, the condensation product of OAA M+3 and acetyl-CoA M+2, was barely detectable, likely because of the low absolute enrichment in OAA and acetyl-CoA. TCA cycle turnover was assessed by analyzing the fractional enrichment of citrate M+1 and malate M+1, both of which were over-represented in the tumors ( Figure 3E ). Therefore, the prominence of M+2 isotopologues is not an artifact of reduced cycle turnover.
To extend the analysis beyond qualitative assessment, we used tcaSIM, a computational tool that simulates metabolic networks involving glycolysis, the TCA cycle, fatty acid oxidation, anaplerosis, and other activities. The utility of this tool is enhanced by the higher and more complex labeling data provided by steady state rather than bolus infusions. tcaSIM can be used to identify relative fluxes that best account for experimental labeling data derived from multiple metabolites simultaneously. This approach avoids pitfalls associated with simple qualitative analysis, such as the possibility that enhanced 13 C labeling in TCA cycle intermediates arises from high enrichment in upstream metabolites rather than bona fide flux changes. Modeling indicated that both PC and PDH fluxes, relative to citrate synthase flux used as a reference, were elevated in the tumors. PDH rather than PC dominated pyruvate entry into the TCA cycle in both tumor and normal lung ( Figure 3F ). The magnitude of PDH flux was positively correlated with the MIB-1 fraction ( Figure S5D ).
Evidence for Lactate Utilization by NSCLC Tumors in Humans and Mice
Although acetyl-CoA enrichment was higher in tumors than lung (Figure 2A ), the absolute enrichment was low ( Figure 4A ). This prompted us to examine whether other blood-borne metabolites contribute to tumor metabolism. Lactate circulates at levels of 1-2 mM and is a fuel for cancer cells under some conditions (Guillaumond et al., 2013; Kennedy et al., 2013; Sonveaux et al., 2008) . To examine the impact of circulating lactate on tumor metabolism, we first compared fractional enrichments between lactate and the glycolytic intermediates 3-PG and phosphoenolpyruvate (PEP) in tumor and lung from all patients. In lung fragments, 3-PG and PEP enrichments were similar to lactate enrichment, and the average ratio of lactate M+3 to 3-PG or PEP M+3 was almost exactly 1.0 ( Figure 4B ). This is expected if lactate arises from glycolysis in the lung. In contrast, lactate enrichment in many tumor fragments exceeded 3PG or PEP enrichment (Table S1) , and the average lactate M+3 exceeded 3-PG or PEP M+3 by $40% ( Figure 4B ). Excess labeling was also propagated into the TCA cycle, as the ratio of enrichment of citrate M+2 to 3-PG or PEP M+3 was higher in tumors ( Figure 4B ). These findings implied that additional labeled substrates contributed to tumor lactate. The most obvious candidate was lactate itself, because lactate imported from the plasma would feed the tumor lactate pool and could provide carbon to the TCA cycle ( Figure 4C ). Indeed, [U-13 C]glucose infusion led to measurable amounts of circulating [U-
13 C]lactate ( Figure 4D ; Table S1 ). Because plasma lactate enrichments were (legend continued on next page) lower than glucose enrichments in both the plasma and tumor, metabolism of 13 C-lactate in the tumor would dilute enrichment in acetyl-CoA and other metabolites relative to tumor glucose enrichment. Given our confirmation by NMR that M+2 isotopologues primarily reflect entry and passage of [U-
13
C]acetylCoA through the TCA cycle, if the fractional M+2 enrichment of TCA cycle intermediates exceeded M+3 in 3-PG and PEP, this would be consistent with contribution of lactate to TCA cycle metabolism. This relationship was observed in several patients, including patient 1 ( Figure 4E ; Table S1 ). Others, like patient 5, demonstrated a pattern of progressive decline in labeling from glucose to all downstream intermediates, similar to the lung (Figure 4E) . These data suggest that some human lung tumors may use lactate as a carbon source.
To examine lactate metabolism directly, mice bearing subcutaneous xenografts derived from cell lines bearing mutations in KRAS (A549 cells, G12S mutation) or EGFR (HCC827 cells, E746-A750 deletion) were infused with [2-
13 C]lactate. This led to rapid and persistent enrichment of the circulating lactate pool ( Figure 4G ), and some enrichment in glucose as lactate was used as a gluconeogenic precursor ( Figure 4F ). Lactate within these tumors was significantly labeled ( Figure 4G ). Enrichment in citrate, malate, and glutamate exceeded enrichment of 3-PG, indicating that these metabolites contained 13 C from imported lactate rather than from labeled glucose.
Individual NSCLC Tumors Display Heterogeneous Degrees of Glucose Metabolism Predicted by an MRI Marker of Perfusion
The extensive metabolic heterogeneity among tumors prompted an examination of factors regulating glucose metabolism. The availability of DCE-MRI data in all patients provided an opportunity to examine the influence of perfusion on tumor metabolism. We first assessed mean signal intensity of DCE images by manually drawing a region of interest (ROI) of a slice chosen for maximal tumor diameter. Tumors were easily dichotomized by qualitative DCE assessment, with several displaying higher time-dependent contrast enhancement and the rest displaying lower enhancement ( Figure 5A ). DCE data were also analyzed as the initial area under the curve 60 s after contrast administration (iAUC60; Figure 5B ). This parameter was previously demonstrated to be stable in human NSCLC over at least 1 week (Ng et al., 2010) , similar to the period of time between imaging and resection in our patients (1-8 days). Analysis of fractional enrichment revealed that metabolites from well-perfused tumors were nearly indistinguishable from adjacent lung, whereas tumors with low iAUC60 values had, on average, higher enrichments compared to either benign lung or tumors with high iAUC60 values ( Figure 5C ). Modeling 13 C enrichment data showed that PDH flux was approximately three times higher in tumors with low-contrast enhancement, whereas PC flux was no different between the groups ( Figure 5D ).
To test whether regions of metabolic heterogeneity existed within individual tumors, we used DCE-MRI to identify anatomic regions of differential contrast enhancement, then selected regions of high and low contrast uptake from the same tumor for metabolite extraction and 13 C enrichment analysis. Patient 8 was a non-smoker with an EGFR-mutated adenocarcinoma measuring 16.1 cm 3 and a high SUV max ( Figure 5E ; Table 1 ).
Although analysis of DCE-MRI of the tumor as a whole identified this as a well-perfused mass ( Figure 5A ), DCE characteristics were dramatically different between the superior and inferior regions ( Figure 5E ). Fragments obtained from the superior and inferior aspects were sectioned into three smaller fragments, extracted, and analyzed for 13 C enrichment. Enrichments in the less well-perfused inferior aspect of the tumor were significantly higher than those in the superior aspect ( Figure 5F ). Both NMR spectroscopy and modeling of mass spectrometry data confirmed differential metabolism in these two areas of the tumor ( Figure S6 ). Patient 9 had a 3.8-cm 3 adenocarcinoma with a low SUV max (Table 1 ) and relatively poor DCE signal throughout (Figure 5A ). However, subtle differences were detected, indicating modestly enhanced signal in the posterior compared to the medial region ( Figures S7A and S7B ). As in patient 8's larger and more FDG-avid tumor, fragments isolated from these two regions displayed differences in 13 C enrichment, with the region of higher DCE signal demonstrating small reductions in 13 C enrichment of lactate, citrate, and other metabolites ( Figure S7C ). Thus, DCE-based assessment of perfusion predicts the extent of glucose's contribution to central metabolism across a clinically relevant range of perfusion and SUV max .
To generate more insight into the relationship between DCE phenotypes and metabolism, RNA sequencing (RNA-seq) was performed on fragments from several tumors. The fragments were then clustered according to their gene expression signatures, using all detected transcripts or a subset of 2,756 genes related to metabolism ( Figure 6A ) (Possemato et al., 2011) . In neither of these unsupervised analyses did the fragments segregate according to the perfusion phenotype. However, gene set enrichment analysis (GSEA) revealed enhanced expression of genes related to glycolysis, oxidative phosphorylation, and the TCA cycle in fragments with low DCE signal, whereas fragments with high DCE signal were enriched for genes related to other nutrients, with many of the 20 most-enriched gene sets related to the lysosome and amino acid metabolism ( Figures 6B and 6C) . Thus, areas of differential DCE signal display altered patterns of gene expression and altered utilization of glucose-derived carbon to supply central metabolism. (legend continued on next page) predict metabolism in vivo. Our work extends other recent efforts to analyze human tumor metabolism with isotope tracers. In particular, two previous studies used a bolus of 13 C-glucose prior to resection to assess NSCLC metabolism (Fan et al., 2009; Sellers et al., 2015) . Like them, we observed evidence of enhanced glycolysis and TCA cycle activity in the tumors and concluded that enhanced pyruvate carboxylation differentiates NSCLC from lung. Our work adds to these studies in several ways. First, we report the molecular and histological characteristics of tumors in the study. This allowed us to demonstrate that enhanced glucose oxidation is observed across diverse histological subtypes and oncogenotypes. Second, we applied a computational assessment of glucose metabolism after persistent exposure to a continuous source of isotope in the circulation. Ultimately, this provided information about both carbon entry into and processing by the TCA cycle, as well as an assessment of the extent to which glucose and other fuels supply oxidative metabolism. Third, integrating multimodality imaging with 13 C-derived data allowed us to compare metabolic markers with other biological features, particularly tissue perfusion. Because these features are suspected to influence metabolism, our approach provides information about the drivers of metabolic complexity in human NSCLC.
Several practicalities of these human studies bear mention. The surgical procedure requires ligation of the pulmonary artery for 15-30 min prior to resection of the diseased lobe. During this time, the lobe and tumor depend on bronchial and collateral circulation for nutrient delivery. Evidence indicates that this did not significantly alter oxygenation of the tumor. The bronchial circulation carries highly oxygenated blood and accounts for a greater contribution to total NSCLC blood flow than the pulmonary circulation (Nguyen-Kim et al., 2015) . Inspection of 13 C labeling indicated hallmarks of enhanced rather than suppressed TCA cycle metabolism, arguing against severe oxygen limitation. These markers persisted even in the occasional patient (not shown) in which the ligation lasted for several hours. Thus, although total blood flow was likely reduced by pulmonary artery ligation, this did not prevent the tissue from engaging in oxidative metabolism. A technical limitation is that the method requires fragments large enough for 13 C studies ($50 mg), inevitably leading to a mixture of malignant and stromal cells. We used presurgical imaging and gross inspection of the tumor to choose fragments composed primarily of viable, malignant cells and histology to confirm this. Although individual tumors contained variable contributions of non-malignant cells, the consistency of key features across the cohort (e.g., enhanced labeling of TCA cycle intermediates) strongly implies that these features are consequences of the malignant cells. Also, some aspects of the modeling assume homogeneity within each fragment with respect to glucose metabolism. Although it is unknown to what extent stromal cells impact metabolic homogeneity within the fragment, we note that the qualitative assessment of labeling and the modeled acetylCoA enrichment agreed very well with each other. Despite these complexities, it was possible to draw several conclusions. First, the data strongly suggest that glycolysis and glucose oxidation via PDH and the TCA cycle are enhanced in NSCLC relative to adjacent benign lung. We observed this phenotype in tumors with mutations in either EGFR or KRAS and presumably in other oncogenic drivers not detected by our molecular analysis. The effect of specific oncogenic mutations is unclear from the current cohort. Although the two KRAS mutant tumors had high levels of 13 C labeling, both also had low DCE signal, which independently predicted high 13 C labeling across the entire group. The overall impression is that multiple oncogenic drivers can specify a phenotype of robust glucose oxidation in vivo. This is consistent with the observation that enhanced glucose metabolism is a shared consequence of many tumorigenic mutations in cultured cancer cells. However, the relationship between glycolysis and glucose oxidation in live tumors has been difficult to ascertain. A common perception is that avid 18 FDG uptake implies enhanced glycolysis and suppressed glucose oxidation, analogous to the conventional understanding of the Warburg effect (Warburg, 1956) . Our data provide strong evidence against the concept of a ''switch'' from oxidative to glycolytic metabolism in NSCLC. Several tumors in the study had SUV max values exceeding 10, yet there was no evidence of suppressed glucose oxidation. We conclude that enhanced glucose uptake in 18 FDG-PET-positive lung tumors supplies enhanced glucose oxidation. Increasing the cohort size will make it possible to test whether particular mutations elicit specific effects on glucose metabolism. Second, entry of 13 C into the TCA cycle was dominated by PDH. PDH-dependent labeling of TCA cycle metabolites was observed in all tumors and was enhanced on average relative to benign lung. Most cancer cell lines also use PDH to supply carbon from glucose to the TCA cycle, although this enzyme is dispensable for survival and proliferation when other nutrients are available in culture (Rajagopalan et al., 2015) . In our cohort, PDH activity correlated with Ki67 staining, suggesting that PDH functions in proliferating malignant cells. PDH was also recently shown to be required for tumor cell survival and/or growth in a KRAS-driven mouse model of lung cancer, arguing that this enzyme is crucial for cancer cells in the lung microenvironment (Davidson et al., 2016) . Third, the tumors displayed low enrichment in acetyl-CoA relative to glucose. This likely indicates that additional substrates enter the metabolic network between glucose and the TCA cycle. Although glucose is a prominent energy source, emerging evidence indicates that tumor cells oxidize other nutrients as well, and in some circumstances may prefer alternative fuels to glucose (Boroughs and DeBerardinis, 2015; Mashimo et al., 2014) . Other potential carbon sources include fatty acids, amino acids, ketones, and macromolecules scavenged from the extracellular space. Our data suggest that lactate, typically viewed as a waste product of cancer cells, can be used as a respiratory substrate by NSCLC tissue. Lactate is abundant and is taken up by monocarboxylate transporters, several of which are expressed in NSCLC (Eilertsen et al., 2014) . Lactate dehydrogenases (LDHs) catalyze NAD + /NADH-dependent exchanges between lactate and pyruvate. Although all LDH isoforms catalyze this reaction in both directions, isoforms containing B subunits encoded by LDHB may favor conversion of lactate to pyruvate and are highly expressed in tissues that use lactate as a fuel. LDHB is highly expressed in a subset of NSCLC tumors and cell lines and correlates with poor survival in adenocarcinoma (McCleland et al., 2013) . It has been proposed that lactate is used as a respiratory substrate in well-perfused areas of solid tumors, with less perfused areas of the same tumors converting glucose to lactate and secreting it (Sonveaux et al., 2008) . Our data do not document net lactate consumption and do not discriminate regional localization of lactate oxidation. However, we do observe that, on average, the contribution of substrates other than [U-13 C]glucose to the TCA cycle was accentuated in regions of high DCE signal. The data suggest a role for PET probes based on lactate and other fuels to help define nutrient preferences in human NSCLC and determine their regulation by the oncogenotype, the microenvironment, and other factors.
Fourth, a key finding was that the metabolic variability among tumors could be predicted by DCE. Tumors with high DCE signal were similar to normal lung in terms of 13 C enrichment, while tumors with lower signal had enhancements of essentially all isotopologues related to the TCA cycle via either PDH or PC. This implies that the predominant metabolic phenotype observed in human NSCLC (enhanced 13 C labeling of TCA cycle intermediates) is related to perfusion. It is unclear whether altered perfusion dictates metabolic activity or whether reduced perfusion and altered metabolism occur in parallel downstream of other factors. In support of the former hypothesis, when considered in light of the low tumor acetyl-CoA enrichment and RNA-seq data, the relationship between 13 C enrichment and DCE suggests that perfusion alters the contributions of various fuels to the TCA cycle ( Figure 6D ). Specifically, high-DCE tumors may oxidize multiple substrates simultaneously, but if perfusion becomes compromised in low-DCE tumors, the contribution of glucose to the TCA cycle rises relative to competing substrates. This may simply reflect the fact that glucose exceeds fat and protein in terms of energy produced per unit of oxygen consumed and may be preferable in states of modestly reduced perfusion. An alternative, but not mutually exclusive, possibility is that less abundant nutrients become depleted in areas of reduced perfusion, whereas glucose remains available by virtue of its high concentration and diffusivity. A similar hypothesis was proposed to explain how interactions between tumor cells and the microenvironment favor a glucose-avid phenotype (Gatenby and Gillies, 2004) . In this setting, enhanced glucose metabolism may be required to provide energy and synthetic precursors to offset reduced availability of other fuels and macromolecules from the circulation. We capitalized on the excellent spatial resolution of DCE-MRI to perform regional analysis within individual tumors. This produced evidence of regional heterogeneity of metabolic flux in solid tumors. Notably, the data suggest that the influence of perfusion may override the intrinsic metabolic preferences set by the genetics of the tumor. For example, patient 8's tumor contained an L858R mutation in EGFR, yet metabolic activity varied considerably across the tumor in correlation with the DCE phenotype. A key emerging question is whether metabolic vulnerabilities also display such striking regional heterogeneity within individual tumors. This would have major implications for the prospects of metabolic therapy in cancer.
In summary, we report the power and practicality of combining clinical imaging and 13 C enrichment in human cancer. Our data suggest that tumor metabolism is significantly and predictably regulated by the microenvironment and that local alterations of metabolism can be identified prior to surgery. This technique enables a rational approach to sample procurement. Given the ever-expanding repertoire of context-specific metabolic pathways in cancer cells (Boroughs and DeBerardinis, 2015) , this method should greatly increase the information yield of experiments involving isotope tracers. It should now be possible to identify and preselect regions using alternative substrates to supply the TCA cycle and to test specific hypotheses related to interactions between the microenvironment and metabolic preferences. Because DCE and other acquisition methods of mpMRI are suitable for mouse models of cancer, it will also be possible to use this approach in experimental systems where the cost of infusions is low and control of experimental parameters is high.
EXPERIMENTAL PROCEDURES
Additional detail is in Supplemental Experimental Procedures.
Clinical Protocol
Nine patients with untreated NSCLC were enrolled in an IRB protocol after obtaining informed consent. On the day of surgery, [U-13 C]glucose was introduced as described previously (Maher et al., 2012) . Standard surgical procedures were followed, with the majority of cases being robotic lobectomies. Tissue fragments were immediately frozen in liquid nitrogen. Histological analyses were conducted by pathologists blinded to the metabolic results. Exons 18-21 of EGFR were bi-directionally Sanger sequenced using lab-developed primers. Mutation analysis for KRAS codons 12, 13, 61, and 146 was performed on a Sequenom Mass ARRAY system (MALDI-TOF) with manual calling.
Multi-parametric Magnetic Resonance Imaging
MRIs occurred 8 or fewer days before surgery. Coronal and axial T2-weighted images were used to localize the lesion and acquire measurements. DCE and DWI were performed within the same examination.
Mass Spectrometry and NMR Spectroscopy
Blood obtained during infusions was used to measure plasma glucose enrichment as described previously (Maher et al., 2012) . Tissue samples (50-100 mg) were added to 50:50 methanol:water for extraction. Gas chromatography (GC)-MS and NMR were performed as described previously (Cheng et al., 2011; Maher et al., 2012) . C]lactate (Cambridge Isotope Laboratories) was infused via syringe pump for 120 min at a rate of 150 ml over 10 min and 2 ml/min until the end of the infusion. Blood samples of $50 ml were obtained periodically. Animals were euthanized at the end of the infusion, then tumors were harvested, rinsed briefly in cold saline, and frozen in liquid nitrogen.
Mouse Studies

RNA Sequencing
Tumor samples were homogenized, and RNA was extracted. 3 mg RNA was processed for library preparation and sequencing. Raw reads were aligned to human genome assembly hg19. A set of 2,756 human metabolic genes (Possemato et al., 2011) was used for GSEA to define differentially expressed pathways between samples with high or low DCE signal.
Statistics
Patient-matched samples were analyzed by paired Student's t test. Inter-tumor analysis of contrast enhancement and relative fractional enrichments was analyzed by unpaired Student's t tests. Correlation plots were analyzed with Pearson's product-moment correlation coefficients of the trendlines. All data were considered significant if p < 0.05.
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